New crown inactivated vaccine emergency vaccination of hundreds of thousands of overseas parallel controls zero infection
Science and Technology Daily, Beijing, September 10 (Reporter Qu Jian) The head of Sinopharm China Biotechnology recently revealed in an interview with the media about the emergency use of the new crown inactivated vaccine and the status of overseas phase III clinical research that the two new crowns inactivated by Sinopharm China Biotechnology Hundreds of thousands of people have been vaccinated with the vaccine, and there has been no obvious adverse reaction, and no one has been infected; among them, tens of thousands of people who went to overseas high-risk countries and regions after vaccination have had no infection so far.
According to Zhou Song, the general counsel of Sinopharm China Biology, three domestic new crown inactivated vaccines have been approved for clinical trials, and Sinopharm China Biology accounts for two of them. It is also the largest emergency vaccination and the largest number of people.
Zhou Song emphasized that what is more significant is that the emergency use of the new crown inactivated vaccine is aimed at high-risk exposure groups, such as medical staff who treat people infected with the new crown virus, as well as diplomats and foreigners going to high-risk countries. Dispatch employees and Chinese-funded enterprises "Belt and Road" construction personnel and so on.
These tens of thousands of people have been overseas for a few months after being vaccinated. Among them, in the areas where the epidemic broke out, some left-behind employees were infected but they did not.
Parallel control data like this is available in multiple countries, which proves the effectiveness of the vaccine.
Zhang Yuntao, vice president of Sinopharm China Biotech, said that phase I and II clinical studies of the new crown inactivated vaccine were carried out in China, and neutralizing antibodies were produced.
"Neutralizing antibody testing is the gold standard." In overseas Phase III clinical studies, neutralizing antibodies will also be continuously observed.
Neutralizing antibodies are comparable. Overseas trials have expanded races, countries, and populations, and most importantly, they have been recognized overseas, which will be better for future applications.
Zhang Yuntao said that in the past, it was difficult for our vaccines to be exported. There were a series of regulations and clinical restrictions.
Now that our scientific and technological strength is strong, the data of phase I and II clinical trials are recognized overseas, and the direct development of phase III clinical research overseas is a model of international cooperation.
In the future, if China's approval is passed, as long as these countries do clinical research, they can also be legally listed on the market.
He revealed that at present, there are 500 million doses of intentional orders for the new crown inactivated vaccine in the world.